menu
Press Release
| November 27, 2019

Q2 Solutions to Expand Genomics Capabilities and Form a Translational Sciences and Innovation Laboratory, Creating 750 New Jobs in North Carolina over the next 10 years

Morrisville, N.C. – November 27, 2019 – Q2 Solutions, a leading clinical trial laboratory services organization, in collaboration with the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina (EDPNC), announced today the expansion of its genomics capabilities, the formation of a Translational Sciences and Innovation Laboratory (“TSAIL”), and the movement of its global headquarters within the state of North Carolina. 

Genomics is a vital element in the growing field of precision medicine with the potential to transform the way we manage complex diseases. This, coupled with rapid technological advancements in the field, has resulted in an explosive demand for regulatory compliant genomic testing in clinical trials. Expansion of the Q2 Solutions Genomics Center of Excellence in North Carolina will enhance the ability to provide innovative genomic testing in North America, as well as further enabling harmonized genomic testing globally.

Another area of increasing demand by biopharmaceutical companies is for laboratories to provide a range of translational services to bridge late preclinical drug development into early clinical drug development under one roof. The creation of the Q2 Solutions TSAIL will allow customers to access a broad range of services including biomarker assay development, bioinformatics, data analytics, and digital innovations, as well as evaluation of novel technologies within one facility and flexible environment. TSAIL will provide a pathway to circumvent some of the challenges associated with moving biomarkers and technologies from  discovery into clinical trials, thereby helping to accelerate drug development.

“We are thrilled to partner with the state of North Carolina on this exciting job creation project. The market for genomic testing in clinical trials has expanded rapidly over the past 5 years and, with the increased information provided to clinical development programs from genomic data, we are expanding our capacity and offerings in North Carolina,” said Brian O’Dwyer, CEO Q2 Solutions. “To complement the expansion in genomics, we are also creating a dedicated Translational Science and Innovation Laboratory which will provide flexible, rapid and tailored assay development and testing laboratories for our customers who are increasingly seeking to utilize novel translational biomarkers across development programs. This new facility will provide a state-of-the-art solution to the industry with multiple laboratory disciplines under one roof for biomarker development and delivery.”

"Because of our strong biotechnology talent, North Carolina has become a hub for contract research organizations of all sizes,” said Governor Cooper.  “In the fight against disease, innovative research companies like Q2 Solutions get the data to make life-changing drugs available to people who need it faster and safer, and we are proud of our state’s role to help them do that work.”

Planning for the project is well underway, with groundbreaking scheduled in the near future. More information about plans and timelines will be released as they are available.

About Q2 Solutions
Q2 Solutions is a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. With a relentless focus on quality and innovation, Q2 Solutions uses its global experience and scientific expertise to transform science and data into actionable medical insights that help customers improve human health. Q2 Solutions’ industry-leading genomic and bioinformatics services provide customers with DNA and RNA sequencing and other testing as well as the ability to mine data for invaluable insights for drug discovery, precision medicine and clinical development. Q2 Solutions works with clients, using a wide array of technology platforms, to ensure maximum efficiency and quality delivery for every study. A joint venture of IQVIA (formerly QuintilesIMS) and Quest Diagnostics, Q2 Solutions combines the best of each parent organization’s clinical trials laboratory services capabilities to fulfill its mission of treating each sample as if a life depends on it. To learn more, visit www.q2labsolutions.com.